Abstract 3431
Background
An increasing proportion of elderly patients (pts) are now being seen at cancer centres, with an increasing incidence of sarcoma. This has become a growing challenge for health care providers, because of the worse prognosis of these pts and our poor knowledge from trials, were they are underrepresented or excluded.
Methods
We performed a retrospective review of elderly pts with soft tissue and bone sarcomas treated between 2012 and 2017 at Regina Elena National Cancer Institute. Overall, 124 pts, median age of 77 (range 70-92), were evaluated for: surgery, radiotherapy (RT), medical treatment and related toxicities.
Results
The most common histological subtypes were: pleomorphic sarcoma (32%); liposarcoma (17%); leiomyosarcoma (13%); mixofibrosarcoma (9%); bone sarcoma (7%); and others (22%). A total of 107 pts had localized disease at diagnosis and 98 of them had surgical resection. 10 pts received adjuvant chemotherapy (CT) (8 Adriamicin (ADM), 1 Gemcitabine (Gem) and 1 Imatinib (IM)) and 35 pts adjuvant RT. 2 pts, unsuitable for surgery, were treated with RT, and 7 had best supportive care (BSC) (median age: 80, range: 73-85). Of the 17 metastatic pts, 13 were treated with palliative surgery. After surgery, 3 pts had RT and 3 had single agent CT (1 ADM, 1 Epirubicin (EPI) and 1 patient with GIST received IM followed by 2nd line Sunitinib). The remaining 3 pts had BSC due to age > 80 yr and PS 2. 10 non-metastatic pts had recurrent disease and were treated with 1st line CT (3 EPI, 1 Dacabarzine, 2 Gem, 1 Pazopanib, 1 ADM, 1 Docetaxel/Gem, 1 Bleomicine/Vinblastine). 6 received 2 lines of CT after progression (4 Trabectidin and 2 Gem). 13 of 21 pts treated with CT had no toxicities. The most common toxicities observed in 8 pts left were: haematological (37%); gastrointestinal (12%), and transaminitis (25%).
Conclusions
In our analysis, “fit” elderly pts were treated with the same medical treatments as non-elderly pts. Tolerability was fairly good, without discontinuation or hospitalization. Only 8% were treated with BSC, a relevant result considering the median age of our pts. Future studies designed for elderly pts and rare tumours, such as sarcomas, are needed to improve survival rates and quality of life of this poorly represented group of pts.
Clinical trial identification
Legal entity responsible for the study
Regina Elena Sarcoma Group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract